← Back to Search

Cannabinoid

CBD for Diabetic Neuropathy

Phase 2
Waitlist Available
Led By Debra Kimless, M.D.
Research Sponsored by Pure Green
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up four weeks
Awards & highlights

Study Summary

This study is evaluating whether a new drug may help relieve pain for individuals with diabetes.

Eligible Conditions
  • Diabetic Neuropathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~four weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and four weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of treatment-related adverse events as assessed by CTCAE v4.0
Secondary outcome measures
Anxiety as assessed by the Zung Self-Rating Anxiety Scale (SAS)
Pain as assessed by Numerical Pain Rating Scale (NPRS)
Sleep Quality as assessed by Pittsburgh Sleep Quality Index (PSQI)
+1 more

Side effects data

From 2014 Phase 2 trial • 50 Patients • NCT01844687
2%
headache
2%
Blurred Vision
2%
Cold Symptoms
2%
Gastrointestinal Upset
2%
anxiety
100%
80%
60%
40%
20%
0%
Study treatment Arm
Active MJ With 0 mg CBD
Active MJ With 200 mg CBD
Active MJ With 400 mg CBD
Active MJ With 800 mg CBD
Inactive MJ With 0 mg CBD
Inactive MJ With 200 mg CBD
Inactive MJ With 400 mg CBD
Inactive MJ With 800 mg CBD

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CBDExperimental Treatment1 Intervention
Subject will receive a 28-day supply of 20 mg CBD sublingual tablets to be taken 3 times a day for 28 days.
Group II: Placebo ControlPlacebo Group1 Intervention
A placebo sublingual tablet to be taken three times a day for 28 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cannabidiol
FDA approved

Find a Location

Who is running the clinical trial?

Pure GreenLead Sponsor
5 Previous Clinical Trials
174 Total Patients Enrolled
Debra Kimless, M.D.Principal InvestigatorPure Green Pharmaceuticals
4 Previous Clinical Trials
158 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet
2020. "Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04679545.
All > Neuropathy > Peripheral Neuropathy
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top